Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

859 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular imaging using PET for breast cancer.
Kurihara H, Shimizu C, Miyakita Y, Yoshida M, Hamada A, Kanayama Y, Yonemori K, Hashimoto J, Tani H, Kodaira M, Yunokawa M, Yamamoto H, Watanabe Y, Fujiwara Y, Tamura K. Kurihara H, et al. Among authors: hashimoto j. Breast Cancer. 2016 Jan;23(1):24-32. doi: 10.1007/s12282-015-0613-z. Epub 2015 Apr 28. Breast Cancer. 2016. PMID: 25917108 Review.
(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients.
Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto J, Yonemori K, Tani H, Miyakita Y, Kanayama Y, Wada Y, Kodaira M, Yunokawa M, Yamamoto H, Shimizu C, Takahashi K, Watanabe Y, Fujiwara Y, Tamura K. Kurihara H, et al. Among authors: hashimoto j. EJNMMI Res. 2015 Mar 12;5:8. doi: 10.1186/s13550-015-0082-6. eCollection 2015. EJNMMI Res. 2015. PMID: 25853014 Free PMC article.
Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies.
Okuma HS, Koizumi F, Hirakawa A, Nakatochi M, Komori O, Hashimoto J, Kodaira M, Yunokawa M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Okuma HS, et al. Among authors: hashimoto j. Br J Cancer. 2016 Aug 9;115(4):411-9. doi: 10.1038/bjc.2016.184. Epub 2016 Jul 14. Br J Cancer. 2016. PMID: 27415010 Free PMC article. Clinical Trial.
Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Takahashi N, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K. Tanaka R, et al. Among authors: hashimoto j. Oncologist. 2016 Apr;21(4):508-13. doi: 10.1634/theoncologist.2015-0377. Epub 2016 Mar 14. Oncologist. 2016. PMID: 26975863 Free PMC article.
Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers.
Shimoi T, Hashimoto J, Sudo K, Shimomura A, Noguchi E, Shimizu C, Yunokawa M, Yonemori K, Yoshida H, Yoshida M, Kato T, Kinoshita T, Fukuda T, Fujiwara Y, Tamura K. Shimoi T, et al. Among authors: hashimoto j. BMC Cancer. 2021 Oct 21;21(1):1131. doi: 10.1186/s12885-021-08869-3. BMC Cancer. 2021. PMID: 34670536 Free PMC article.
A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.
Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y. Yonemori K, et al. Among authors: hashimoto j. Eur J Cancer. 2019 Mar;109:84-91. doi: 10.1016/j.ejca.2018.11.014. Epub 2019 Jan 28. Eur J Cancer. 2019. PMID: 30703739 Clinical Trial.
Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.
Shimomura A, Yonemori K, Yoshida M, Yoshida T, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Kawachi A, Shimizu C, Fujiwara Y, Tamura K. Shimomura A, et al. Among authors: hashimoto j. Transl Oncol. 2019 Oct;12(10):1386-1394. doi: 10.1016/j.tranon.2019.07.013. Epub 2019 Aug 2. Transl Oncol. 2019. PMID: 31382135 Free PMC article.
Diagnostic performance of (18)F-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis.
Niikura N, Hashimoto J, Kazama T, Koizumi J, Ogiya R, Terao M, Oshitanai R, Morioka T, Tsuda B, Okamura T, Saito Y, Iwaisako K, Iwamoto T, Hayashi N, Imai Y, Tokuda Y. Niikura N, et al. Among authors: hashimoto j. Breast Cancer. 2016 Jul;23(4):662-7. doi: 10.1007/s12282-015-0621-z. Epub 2015 Jun 3. Breast Cancer. 2016. PMID: 26037335
Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors.
Tamura K, Hashimoto J, Tanabe Y, Kodaira M, Yonemori K, Seto T, Hirai F, Arita S, Toyokawa G, Chen L, Yamamoto H, Kawata T, Lindemann J, Esaki T. Tamura K, et al. Among authors: hashimoto j. Cancer Chemother Pharmacol. 2016 Apr;77(4):787-95. doi: 10.1007/s00280-016-2987-9. Epub 2016 Mar 1. Cancer Chemother Pharmacol. 2016. PMID: 26931343 Free PMC article. Clinical Trial.
859 results